Your browser doesn't support javascript.
loading
The Contribution of GWAS Loci in Familial Dyslipidemias.
Ripatti, Pietari; Rämö, Joel T; Söderlund, Sanni; Surakka, Ida; Matikainen, Niina; Pirinen, Matti; Pajukanta, Päivi; Sarin, Antti-Pekka; Service, Susan K; Laurila, Pirkka-Pekka; Ehnholm, Christian; Salomaa, Veikko; Wilson, Richard K; Palotie, Aarno; Freimer, Nelson B; Taskinen, Marja-Riitta; Ripatti, Samuli.
  • Ripatti P; Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
  • Rämö JT; Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
  • Söderlund S; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
  • Surakka I; Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
  • Matikainen N; Research Programs Unit, Diabetes & Obesity, University of Helsinki, and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
  • Pirinen M; Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
  • Pajukanta P; Research Programs Unit, Diabetes & Obesity, University of Helsinki, and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
  • Sarin AP; Endocrinology, Abdominal Center, Helsinki University Hospital, Helsinki, Finland.
  • Service SK; Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
  • Laurila PP; Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California Los Angeles (UCLA), Los Angeles, California, United States of America.
  • Ehnholm C; Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
  • Salomaa V; National Institute for Health and Welfare, Helsinki, Finland.
  • Wilson RK; Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California, United States of America.
  • Palotie A; Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
  • Freimer NB; Public Health Genomics Unit, National Institute for Health and Welfare, Helsinki, Finland.
  • Taskinen MR; Department of Medical Genetics, University of Helsinki, Helsinki, Finland.
  • Ripatti S; Public Health Genomics Unit, National Institute for Health and Welfare, Helsinki, Finland.
PLoS Genet ; 12(5): e1006078, 2016 05.
Article en En | MEDLINE | ID: mdl-27227539
ABSTRACT
Familial combined hyperlipidemia (FCH) is a complex and common familial dyslipidemia characterized by elevated total cholesterol and/or triglyceride levels with over five-fold risk of coronary heart disease. The genetic architecture and contribution of rare Mendelian and common variants to FCH susceptibility is unknown. In 53 Finnish FCH families, we genotyped and imputed nine million variants in 715 family members with DNA available. We studied the enrichment of variants previously implicated with monogenic dyslipidemias and/or lipid levels in the general population by comparing allele frequencies between the FCH families and population samples. We also constructed weighted polygenic scores using 212 lipid-associated SNPs and estimated the relative contributions of Mendelian variants and polygenic scores to the risk of FCH in the families. We identified, across the whole allele frequency spectrum, an enrichment of variants known to elevate, and a deficiency of variants known to lower LDL-C and/or TG levels among both probands and affected FCH individuals. The score based on TG associated SNPs was particularly high among affected individuals compared to non-affected family members. Out of 234 affected FCH individuals across the families, seven (3%) carried Mendelian variants and 83 (35%) showed high accumulation of either known LDL-C or TG elevating variants by having either polygenic score over the 90th percentile in the population. The positive predictive value of high score was much higher for affected FCH individuals than for similar sporadic cases in the population. FCH is highly polygenic, supporting the hypothesis that variants across the whole allele frequency spectrum contribute to this complex familial trait. Polygenic SNP panels improve identification of individuals affected with FCH, but their clinical utility remains to be defined.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Apolipoproteínas B / Enfermedad de la Arteria Coronaria / Dislipidemias / Hiperlipidemia Familiar Combinada Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Apolipoproteínas B / Enfermedad de la Arteria Coronaria / Dislipidemias / Hiperlipidemia Familiar Combinada Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article